マサチューセッツ州における濾胞性リンパ腫の臨床試験
マサチューセッツ州内の拠点で、濾胞性リンパ腫に関する20件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
12歳以上 · 全性別 · 2026/10/02更新 · NCT07215910A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716Epco, Zanu, Ritux for R/R FL or MZL
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06563596A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Boston
- Research Site, Boston
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/21更新 · NCT06549595NEO100 and High-Grade Meningioma
- Tufts Medical Center, Boston
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/15更新 · NCT05023018A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06091254SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Epcoritamab and Rituximab for First-line Follicular Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT05783609A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/20更新 · NCT06911502CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/16更新 · NCT06026319Odronextamab in Low Tumor Volume Advanced FL
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT07128641Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT06510361Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/30更新 · NCT04669171AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Massachusetts Memorial Medical Center, Worcester
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363Emapalumab Prevention of CAR-T Cell Associated Toxicities
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2025/11/14更新 · NCT06550141SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
- Shwachman-Diamond Syndrome Alliance Inc., Woburn
被験者募集中観察研究
全年齢 · 全性別 · 2025/05/31更新 · NCT06999954ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。